Induction of regulatory T cells and efficacy of low-dose interleukin-2 in systemic sclerosis: interventional open-label phase 1-phase 2a study.

ABSTRACT:

Background

Systemic sclerosis (SSc) is a chronic autoimmune disease, with impaired immune response, increased fibrosis and endothelial dysfunction. Regulatory T cells (Tregs), which are essential to control inflammation, tissue repair and autoimmunity, have a decreased frequency and impaired function in SSc patients. Low-dose interleukin-2 (IL-2_LD) can expand and activate Tregs and has, therefore, a therapeutic potential in SSc.

Objective

We aimed to assess the safety and biological efficacy of IL-2_LD in patients with SSc.

Methods

As part of the TRANSREG open-label phase IIa basket trial in multiple autoimmune diseases, we studied nine patients with SSc without severe organ involvement. Patients received 1 million international units (MIU)/day of

SUBMITTER: Barde F 

PROVIDER: S-EPMC11002342 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature